PubMed

Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial.

Greenspan SL, Emkey RD, Bone HG, Weiss SR, Bell NH, Downs RW, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A.

Ann Intern Med. 2002 Dec 3;137(11):875-83.PMID: 12458987 [PubMed - indexed for MEDLINE]Related articlesFree article

Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group.

Bone HG, Greenspan SL, McKeever C, Bell N, Davidson M, Downs RW, Emkey R, Meunier PJ, Miller SS, Mulloy AL, Recker RR, Weiss SR, Heyden N, Musliner T, Suryawanshi S, Yates AJ, Lombardi A.

J Clin Endocrinol Metab. 2000 Feb;85(2):720-6.PMID: 10690882 [PubMed - indexed for MEDLINE]Related articlesFree article

Changes in bone density and turnover after alendronate or estrogen withdrawal.

Wasnich RD, Bagger YZ, Hosking DJ, McClung MR, Wu M, Mantz AM, Yates JJ, Ross PD, Alexandersen P, Ravn P, Christiansen C, Santora AC 2nd; Early Postmenopausal Intervention Cohort Study Group.

Menopause. 2004 Nov-Dec;11(6 Pt 1):622-30.PMID: 15545790 [PubMed - indexed for MEDLINE]Related articles

Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.

Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM; Fracture Intervention Trial Long-Term Extension Research Group.

J Bone Miner Res. 2004 Aug;19(8):1259-69. Epub 2004 Mar 29.PMID: 15231012 [PubMed - indexed for MEDLINE]Related articles

Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial.

Ravn P, Bidstrup M, Wasnich RD, Davis JW, McClung MR, Balske A, Coupland C, Sahota O, Kaur A, Daley M, Cizza G.

Ann Intern Med. 1999 Dec 21;131(12):935-42.PMID: 10610644 [PubMed - indexed for MEDLINE]Related articlesFree article

Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial.

Greenspan SL, Resnick NM, Parker RA.

JAMA. 2003 May 21;289(19):2525-33.PMID: 12759324 [PubMed - indexed for MEDLINE]Related articlesFree article

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P, McClung M, Balske A, Thompson D, Daley M, Yates AJ.

N Engl J Med. 1998 Feb 19;338(8):485-92.PMID: 9443925 [PubMed - indexed for MEDLINE]Related articlesFree article

Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.

Gallagher JC, Fowler SE, Detter JR, Sherman SS.

J Clin Endocrinol Metab. 2001 Aug;86(8):3618-28.PMID: 11502787 [PubMed - indexed for MEDLINE]Related articlesFree article

Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, De Deuxchaisnes CN, Geusens P, Hosking D, Jaeger P, Kaufman JM, Leite M, Leon J, Liberman U, Menkes CJ, Meunier PJ, Reid I, Rodriguez J, Romanowicz A, Seeman E, Vermeulen A, Hirsch LJ, Lombardi A, Plezia K, Santora AC, Yates AJ, Yuan W.

Bone. 1996 Feb;18(2):141-50. Erratum in: Bone 1996 Jul;19(1):78. PMID: 8833208 [PubMed - indexed for MEDLINE]Related articles

Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.

Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ; MK-677/Alendronate Study Group.

J Clin Endocrinol Metab. 2001 Mar;86(3):1116-25.PMID: 11238495 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lombardi A, Santora AC, Cummings SR; FLEX Research Group.

JAMA. 2006 Dec 27;296(24):2927-38.PMID: 17190893 [PubMed - indexed for MEDLINE]Related articlesFree article

Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women.

Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd.

Am J Med. 1997 Oct;103(4):291-7.PMID: 9382121 [PubMed - indexed for MEDLINE]Related articles

Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.

Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH.

Osteoporos Int. 2005 Apr;16(4):372-9. Epub 2005 Jan 15.PMID: 15654581 [PubMed - indexed for MEDLINE]Related articles

Alveolar and postcranial bone density in postmenopausal women receiving hormone/estrogen replacement therapy: a randomized, double-blind, placebo-controlled trial.

Civitelli R, Pilgram TK, Dotson M, Muckerman J, Lewandowski N, Armamento-Villareal R, Yokoyama-Crothers N, Kardaris EE, Hauser J, Cohen S, Hildebolt CF.

Arch Intern Med. 2002 Jun 24;162(12):1409-15. Erratum in: Arch Intern Med. 2004 Jan 12;164(1):96. PMID: 12076241 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women.

Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH.

JAMA. 2002 May 22-29;287(20):2668-76.PMID: 12020302 [PubMed - indexed for MEDLINE]Related articlesFree article

Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.

Greenspan SL, Resnick NM, Parker RA.

J Clin Endocrinol Metab. 2005 May;90(5):2762-7. Epub 2005 Feb 15.PMID: 15713726 [PubMed - indexed for MEDLINE]Related articlesFree article

The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.

Michalská D, Stepan JJ, Basson BR, Pavo I.

J Clin Endocrinol Metab. 2006 Mar;91(3):870-7. Epub 2005 Dec 13.PMID: 16352692 [PubMed - indexed for MEDLINE]Related articlesFree article

Alendronate increases spine and hip bone mineral density in women with postmenopausal osteoporosis who failed to respond to intermittent cyclical etidronate.

Watts NB, Becker P.

Bone. 1999 Jan;24(1):65-8.PMID: 9916786 [PubMed - indexed for MEDLINE]Related articles

Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.

Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.

J Bone Miner Res. 1998 Sep;13(9):1431-8.PMID: 9738515 [PubMed - indexed for MEDLINE]Related articles

Summaries for patients. Bone loss after stopping estrogen or alendronate therapy.

[No authors listed]

Ann Intern Med. 2002 Dec 3;137(11):I31. No abstract available. PMID: 12459003 [PubMed - indexed for MEDLINE]Related articlesFree article